Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
03 oct. 2024 08h30 HE
|
Journey Medical Corporation
SCOTTSDALE, Ariz., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses...
Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements
20 sept. 2024 08h30 HE
|
Fortress Biotech, Inc.
MIAMI, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on acquiring and advancing assets to...
Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024
16 sept. 2024 07h30 HE
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the...
Fortress Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference
04 sept. 2024 08h30 HE
|
Fortress Biotech, Inc.
MIAMI, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term...
Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
13 août 2024 16h05 HE
|
Fortress Biotech, Inc.
PDUFA goal date of November 4, 2024 for DFD-29 for the treatment of inflammatory lesions and erythema of rosacea in adults FDA accepted Biologics License Application resubmission for cosibelimab to...
Journey Medical Corporation Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
12 août 2024 16h01 HE
|
Journey Medical Corporation
New Drug Application for DFD-29 to treat rosacea under FDA review; PDUFA goal date of November 4, 2024 Total revenues for the second quarter ended June 30, 2024 were $14.9 million, a 14% increase...
Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates
12 août 2024 08h30 HE
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial...
Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027
25 juil. 2024 08h30 HE
|
Fortress Biotech, Inc.
MIAMI, July 25, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”, or the “Company”), an innovative biopharmaceutical company focused on acquiring and advancing assets to...
Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma
25 juil. 2024 07h30 HE
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that the...
GC Cell and Checkpoint Therapeutics Advance Collaborative Cancer Research
15 juil. 2024 08h00 HE
|
Checkpoint Therapeutics, Inc
Collaboration explores the potential synergistic effects of Checkpoint’s anti-PD-L1, cosibelimab, in combination with the autologous T cell therapy, Immuncell-LC YONGIN, South Korea and WALTHAM,...